|
KMID : 1142020220570000006
|
|
Blood Research
2022 Volume.57 No. 0 p.6 ~ p.10
|
|
|
Evaluation and management of platelet transfusion refractoriness
|
|
Youk Hee-Jeong
Hwang Sang-Hyun
Oh Heung-Bum
Ko Dae-Hyun
|
|
|
Abstract
|
|
|
|
Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common is human leukocyte antigen (HLA) class I molecules. PTR caused by anti-HLA antibodies is usually managed by transfusing HLA-matched platelets. Therefore, it is important, especially for hemato-oncologists who frequently perform transfusion, to accurately diagnose whether the cause of platelet transfusion failure is alloimmune or non-immunological when determining the treatment direction for the patient. In this review, we discuss the definitions, causes, countermeasures, and prevention methods of PTR.
|
|
|
KEYWORD
|
|
|
Platelet transfusion refractoriness, Platelet transfusion, Human leukocyte antigen, HLA-matched, Platelet count
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|